Trump Administration Announces Medicaid Drug Discount Agreements with Biotech Companies
The Trump administration plans to announce drug-pricing agreements with several midsized biotech companies on Monday, requiring the companies to provide discounts on outpatient drugs to state Medicaid programs aligned with foreign prices. Participation by state Medicaid programs is optional. In exchange, participating companies will be exempt from pilot programs forcing similar discounts in Medicare, and relief from tariffs is part of some discussions. The agreements represent a new federal approach to Medicaid drug pricing, though states retain discretion on participation.
These agreements could lower state Medicaid drug costs but require state action to implement, potentially creating operational and policy decisions around adoption and formulary management.
Pharmacy · Finance
You might also like